The drugmaker is the sole patent holder of Mounjaro’s active pharmaceutical ingredient, tirzepatide. Eli Lilly is requesting monetary damages and that these companies be blocked from selling tirzepatide marketed as Mounjaro.
Mounjaro is a glucagon-like peptide-1 receptor agonist, which is the same drug class as Ozempic and Wegovy, two Novo Nordisk drugs that have been in short supply for about a year because of weight loss trends. Novo Nordisk also filed similar lawsuits against spas, clinics and compounding pharmacies in mid-2023 along with claims of companies selling unapproved copycats.
“Products claiming to contain tirzepatide that are made and/or distributed by compounding pharmacies or distributed by counterfeit sources have not been reviewed by the U.S. FDA or global regulatory agencies for safety, quality, or efficacy; are not FDA-approved like Mounjaro; and may expose patients to potentially serious health risks,” Eli Lilly said in a Sept. 19 news release.
The lawsuits are in Arizona, Florida, Georgia, Minnesota, South Carolina, Texas and Utah.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
